Page last updated: 2024-09-05

sorafenib and navitoclax

sorafenib has been researched along with navitoclax in 3 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(navitoclax)
Trials
(navitoclax)
Recent Studies (post-2010) (navitoclax)
6,5207305,25142915401

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)navitoclax (IC50)
Bcl-2-like protein 11Homo sapiens (human)0.0043
Apoptosis regulator Bcl-2Homo sapiens (human)0.0091
Bcl-2-like protein 1Homo sapiens (human)0.0168
Aspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)1.0925
Bcl-2-like protein 2Homo sapiens (human)0.07

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Giaccone, G; Killian, KJ; Lee, C; Lee, HS; Luo, J; Meltzer, PS; Petrini, I; Roncalli, M; Santoro, A; Steinberg, SM; Tsokos, M; Wang, Y; Zucali, PA1
Chen, Y; Li, J; Li, W; Liu, X; Wan, J; Yu, C1

Other Studies

3 other study(ies) available for sorafenib and navitoclax

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors.
    Cell death & disease, 2012, Jul-19, Volume: 3

    Topics: Adult; Aged; Aged, 80 and over; Algorithms; Aniline Compounds; Animals; Apoptosis Regulatory Proteins; Autophagy; bcl-X Protein; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Comparative Genomic Hybridization; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; DNA Copy Number Variations; Female; Humans; Indoles; Male; Mice; Mice, Nude; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms, Glandular and Epithelial; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Pyrroles; RNA Interference; RNA, Small Interfering; Sorafenib; Sulfonamides; Thymus Neoplasms; TOR Serine-Threonine Kinases; Transplantation, Heterologous

2012
ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1/WAF1)) in human cancer cells.
    British journal of pharmacology, 2014, Volume: 171, Issue:13

    Topics: Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays

2014